Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Cyclacel Pharmaceuticals, Inc..
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Cyclacel Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00999401
First received: October 19, 2009
Last updated: November 7, 2011
Last verified: November 2011

October 19, 2009
November 7, 2011
February 2009
March 2012   (final data collection date for primary outcome measure)
maximum tolerated dose [ Time Frame: 1-3 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00999401 on ClinicalTrials.gov Archive Site
  • tumor response rate [ Time Frame: 1-3 months ] [ Designated as safety issue: No ]
  • pharmacodynamic effects in skin and peripheral mononuclear cells [ Time Frame: 1-3 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially. The secondary objectives are to evaluate antitumor activity of this sequential treatment and to explore the pharmacodynamic effect of this treatment in skin and peripheral blood mononuclear cells.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Solid Tumors
Drug: sapacitabine and seliciclib
sequential administration of sapacitabine and seliciclib
Experimental: sapacitabine and seliciclib
Sequential administration of sapacitabine and seliciclib
Intervention: Drug: sapacitabine and seliciclib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
September 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Incurable advanced solid tumors that are no longer responding to conventional therapy or for which no effective therapy exists
  • Age 18 years or older
  • ECOG 0-2
  • Life expectancy ≥ 3 months
  • Evaluable disease
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate liver function
  • At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
  • Able to swallow capsules
  • At least 3 weeks from major surgery
  • Agree to practice effective contraception
  • Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

  • Previously untreated CNS metastases or progressive CNS metastases
  • Currently receiving radiotherapy, biological therapy, or any other investigational agents
  • Uncontrolled intercurrent illness including
  • Pregnant or lactating women
  • Known to be HIV-positive
  • A history of active hepatitis B and/or hepatitis C infection
Both
18 Years and older
No
United States
 
NCT00999401
CYC682-07
No
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
Not Provided
Principal Investigator: Geoffrey Shapiro, M.D. Dana-Farber Cancer Institute
Cyclacel Pharmaceuticals, Inc.
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP